

FORM PTO 1390 (REV 5-95) US DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY DOCKET NUMBER 2002_0053A
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. §371		U.S. APPLICATION NO. (if known, see 37 CFR 1.15) NEW 10/031396
International Application No. PCT/JP00/04815	International Filing Date July 18, 2000	Priority Date Claimed July 19, 1999
<p>Title of Invention A METHOD FOR CONSTRUCTING RECOMBINANT ADENOVIRUS VECTOR</p>		
<p>Applicant(s) For DO/EO/US Junichi MIYAZAKI, Fumi TASHIRO</p>		
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p>		
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. §371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. §371. 3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. §371(c)(2)) <ul style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) 6. <input checked="" type="checkbox"/> A translation of the International Application into English (35 U.S.C. §371(c)(2)). ATTACHMENT A 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. §371(c)(3)). <ul style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19. 9. <input checked="" type="checkbox"/> An unexecuted oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)). ATTACHMENT B 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)). 		
<p>Items 11. to 14. below concern other document(s) or information included:</p>		
<ol style="list-style-type: none"> 11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. ATTACHMENT C 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. ATTACHMENT D <ul style="list-style-type: none"> <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> Other items or information: 		

THE COMMISSIONER IS AUTHORIZED
TO CHARGE ANY DEFICIENCY IN THE
FEE FOR THIS PAPER TO DEPOSIT
ACCOUNT NO.23-0975.

U.S. APPLICATION NO. NEW 10/031396	INTERNATIONAL APPLICATION NO. PCT/JP00/04815	ATTORNEY'S DOCKET NO. 2002 0053A																
<p>15. <input checked="" type="checkbox"/> The following fees are submitted</p> <p>BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):</p> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 70%;">Neither international preliminary examination fee nor international search fee paid to USPTO and International Search Report not prepared by the EPO or JPO</td> <td style="width: 30%; text-align: right;">\$1040.00</td> </tr> <tr> <td>International Search Report has been prepared by the EPO or JPO</td> <td style="text-align: right;">\$ 890.00</td> </tr> <tr> <td>International preliminary examination fee not paid to USPTO but international search paid to USPTO</td> <td style="text-align: right;">\$ 740.00</td> </tr> <tr> <td>International preliminary examination fee paid to USPTO but claims did not satisfy provisions of PCT Article 33(1)-(4)</td> <td style="text-align: right;">\$ 690.00</td> </tr> <tr> <td>International preliminary examination fee paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)</td> <td style="text-align: right;">\$ 100.00</td> </tr> </table>		Neither international preliminary examination fee nor international search fee paid to USPTO and International Search Report not prepared by the EPO or JPO	\$1040.00	International Search Report has been prepared by the EPO or JPO	\$ 890.00	International preliminary examination fee not paid to USPTO but international search paid to USPTO	\$ 740.00	International preliminary examination fee paid to USPTO but claims did not satisfy provisions of PCT Article 33(1)-(4)	\$ 690.00	International preliminary examination fee paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)	\$ 100.00	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; text-align: center;">CALCULATIONS</td> <td style="width: 50%; text-align: center;">PTO USE ONLY</td> </tr> <tr> <td colspan="2" style="height: 40px;"></td> </tr> </table>	CALCULATIONS	PTO USE ONLY				
Neither international preliminary examination fee nor international search fee paid to USPTO and International Search Report not prepared by the EPO or JPO	\$1040.00																	
International Search Report has been prepared by the EPO or JPO	\$ 890.00																	
International preliminary examination fee not paid to USPTO but international search paid to USPTO	\$ 740.00																	
International preliminary examination fee paid to USPTO but claims did not satisfy provisions of PCT Article 33(1)-(4)	\$ 690.00																	
International preliminary examination fee paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)	\$ 100.00																	
CALCULATIONS	PTO USE ONLY																	
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$890.00																
<p>Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</p>		\$																
<table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 25%;">Claims</th> <th style="width: 25%;">Number Filed</th> <th style="width: 25%;">Number Extra</th> <th style="width: 25%;">Rate</th> </tr> </thead> <tbody> <tr> <td>Total Claims</td> <td>-20 =</td> <td></td> <td>X \$18.00</td> </tr> <tr> <td>Independent Claims</td> <td>4 - 3 =</td> <td>1</td> <td>X \$84.00</td> </tr> <tr> <td colspan="3">Multiple dependent claim(s) (if applicable)</td> <td>+ \$280.00</td> </tr> </tbody> </table>		Claims	Number Filed	Number Extra	Rate	Total Claims	-20 =		X \$18.00	Independent Claims	4 - 3 =	1	X \$84.00	Multiple dependent claim(s) (if applicable)			+ \$280.00	\$
Claims	Number Filed	Number Extra	Rate															
Total Claims	-20 =		X \$18.00															
Independent Claims	4 - 3 =	1	X \$84.00															
Multiple dependent claim(s) (if applicable)			+ \$280.00															
TOTAL OF ABOVE CALCULATIONS =		\$974.00																
<p><input type="checkbox"/> Small Entity Status is hereby asserted. Above fees are reduced by 1/2.</p>		\$																
SUBTOTAL =		\$974.00																
<p>Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</p>		+ \$																
TOTAL NATIONAL FEE =		\$974.00																
<p>Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +</p>		\$																
TOTAL FEES ENCLOSED =		\$974.00																
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 70%;"></td> <td style="width: 30%; text-align: right;">Amount to be refunded</td> </tr> <tr> <td colspan="2" style="height: 20px;"></td> </tr> <tr> <td colspan="2" style="height: 20px;"></td> </tr> </table>			Amount to be refunded					\$										
	Amount to be refunded																	
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 70%;"></td> <td style="width: 30%; text-align: right;">Amount to be charged</td> </tr> <tr> <td colspan="2" style="height: 20px;"></td> </tr> <tr> <td colspan="2" style="height: 20px;"></td> </tr> </table>			Amount to be charged					\$										
	Amount to be charged																	
<p>a. <input checked="" type="checkbox"/> A check in the amount of <u>\$9740.00</u> to cover the above fees is enclosed. A duplicate copy of this form is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. 23-0975 in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>23-0975</u>.</p>																		
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p>																		
<p>19. CORRESPONDENCE ADDRESS</p> <p style="text-align: center;">  000513 PATENT TRADEMARK OFFICE </p>																		
<p>By: <u>Warren M. Cheek, Jr.</u> Warren M. Cheek, Jr., Registration No. 33,367</p> <p>WENDEROTH, LIND & PONACK, L.L.P. 2033 "K" Street, N.W., Suite 800 Washington, D.C. 20006-1021 Phone: (202) 721-8200 Fax: (202) 721-8250</p> <p style="text-align: right;">January 18, 2002</p>																		

[CHECK NO. 48444]

[2002_0053A]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Junichi MIYAZAKI et al. : Attn: **BOX PCT**Serial No. NEW : **Docket No. 2002_0053A**

Filed January 18, 2002 :

**A METHOD FOR CONSTRUCTING RECOMBINANT
ADENOVIRUS VECTOR**

[Corresponding to PCT/JP00/04815

Filed July 18, 2000]

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents,
Washington, DC 20231

Sir:

Prior to calculating the filing fee, please amend the above-identified application as follows:

IN THE SPECIFICATION

Page 1, immediately after the title, please insert:

This application is a 371 of PCT/JP00/04815 filed July 18, 2000.

IN THE CLAIMS

Please amend the claims as follows:

4. (Amended) The method according to claim 1, wherein the cell line producing adenovirus E1 protein is 293 cell derived from human fetal kidney cells.

8. (Amended) The method according to claim 5, wherein the cell line producing recombinase and adenovirus E1 protein is 293 cell derived from human fetal kidney cells which produces the recombinase.

REMARKS

The specification has been amended to reflect the national stage status. In addition, the multiple dependencies of the claims have been eliminated to reduce the PTO filing fee.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached pages are captioned "Version with markings to show changes made".

Favorable action on the merits is solicited.

Respectfully submitted,

Junichi MIYAZAKI et al.

By

Warren Cheek Jr.

Warren M. Cheek, Jr.
Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
January 18, 2002

Version with Markings to
Show Changes Made

JG13 Rec'd PCT/PTO 18 JAN 2002

DESCRIPTION

A Method for Constructing Recombinant Adenovirus Vector

This application is a 371 of PCT/JP00/04815 filed July 18, 2000.
5

Technical Filed

The invention of the present application relates to a method for constructing a recombinant adenovirus vector. More specifically, the invention of
10 the present application relates to a method for constructing a recombinant adenovirus vector which is useful for introducing genes into mammalian cells, and genetic engineering materials for said method.

15

Background Art

In recent years, the life science has made a long stride progress due to the accumulation of knowledge and the development of various technology in the fields of molecular biology, molecular genetics and the like, whereby a number of
20 information for life phenomena can now be obtained. Research and development are being vigorously carried out in various fields, and the analysis of gene functions has a significant weight among such research and development. Specifically, various technology for introducing an isolated gene into cells or organs in vivo, and vectors which are used for such technology, have been
25 developed.

Vectors of a number of types which are used for introducing genes to a mammalian cell have also been developed. In recent years, vectors produced by utilizing virus (virus vectors) are drawing attention. Among the virus vectors, an
30 adenovirus vector, in particular, can be infected not only to dividing cells but also

CLAIMS

1. A method for constructing a recombinant adenovirus vector having a DNA sequence consisting of an adenovirus genome DNA and an expression cassette, 5 which comprises:

constructing a recombinant cosmid/adenovirus vector by inserting and ligating a cosmid sequence having recombinase recognition sequences at both ends and the expression cassette into a site of the adenovirus genome DNA where E1 region or E1 and E3 regions are deleted;

10 cotransfected this recombinant cosmid/adenovirus vector and a recombinase-expression vector into a cell line producing adenovirus E1 protein; and

deleting the cosmid vector sequence from the recombinant cosmid/adenovirus vector in the cells.

15 2. The method according to claim 1, wherein the recombinase is Cre recombinase and the recognition sequences thereof are loxP sequences.

20 3. The method according to claim 1, wherein the recombinase is FLP recombinase and the recognition sequences thereof are FRT sequences.

✓ 4. (Amended)

4. The method according to any of claims 1 to 3, wherein the cell line producing adenovirus E1 protein is 293 cell derived from human fetal kidney cells.

25 5. A method for constructing a recombinant adenovirus vector having a DNA sequence consisting of an adenovirus genome DNA and an expression cassette, which comprises:

constructing a recombinant cosmid/adenovirus vector by inserting and ligating a cosmid sequence having recombinase recognition sequences at both 30 ends and the expression cassette into a site of the adenovirus genome DNA where

E1 region or E1 and E3 regions are deleted;

transfected this recombinant cosmid/adenovirus vector into a cell line
producing recombinase and adenovirus E1 protein; and

5 deleting the cosmid vector sequence from the recombinant
cosmid/adenovirus vector in the cells.

6. The method according to claim 5, wherein the recombinase is Cre
recombinase and the recognition sequences thereof are loxP sequences.

10 7. The method according to claim 5, wherein the recombinase is FLP
recombinase and the recognition sequences thereof are FRT sequences.

(Amended)

8. The method according to ~~any of claims~~ 5 to 7, wherein the cell line
producing recombinase and adenovirus E1 protein is 293 cell derived from human
15 fetal kidney cells which produces the recombinase.

9. A cosmid/adenovirus vector, which comprises a cosmid sequence having
recombinase recognition sequences at both ends in a site of the adenovirus
genome DNA where E1 region or E1 and E3 regions are deleted.

20 10. The cosmid/adenovirus vector of claim 9, wherein the recombinase is Cre
recombinase and the recognition sequences thereof are loxP sequences.

25 11. The cosmid/adenovirus vector of claim 9, wherein the recombinase is FLP
recombinase and the recognition sequences thereof are FRT sequences.

12. A 293 cell line derived from human fetal kidney cells, which produces FLP
recombinase.

4/PYD>

1

JC13 Rec'd PCT/PTO 18 JAN 2002

DESCRIPTION**A Method for Constructing Recombinant Adenovirus Vector**

5

Technical Filed

The invention of the present application relates to a method for constructing a recombinant adenovirus vector. More specifically, the invention of
10 the present application relates to a method for constructing a recombinant adenovirus vector which is useful for introducing genes into mammalian cells, and genetic engineering materials for said method.

15

Background Art

In recent years, the life science has made a long stride progress due to the accumulation of knowledge and the development of various technology in the fields of molecular biology, molecular genetics and the like, whereby a number of
20 information for life phenomena can now be obtained. Research and development are being vigorously carried out in various fields, and the analysis of gene functions has a significant weight among such research and development. Specifically, various technology for introducing an isolated gene into cells or organs in vivo, and vectors which are used for such technology, have been
25 developed.

Vectors of a number of types which are used for introducing genes to a mammalian cell have also been developed. In recent years, vectors produced by utilizing virus (virus vectors) are drawing attention. Among the virus vectors, an
30 adenovirus vector, in particular, can be infected not only to dividing cells but also

to non-dividing cells, thereby can be prepared at a high virus titer. In addition, as an adenovirus vector can express the targeted gene under the control of enhancers and promoters of various combinations, the medical application of the adenovirus vector to gene therapy have been studied.

5

Up to now, a number of methods of constructing a recombinant adenovirus vector, such as a method of utilizing in vivo homologous recombination and a method by in vitro ligation, have been developed. When a recombinant adenovirus vector having the adenovirus genome in which the E1 region has been deleted is used, the introduced gene is expressed but the infectious viral particles are not produced. Therefore, a recombinant adenovirus vector is utilized especially as a useful means for introducing genes in gene therapy or the like.

Adenovirus vector has a number of advantages as compared with other virus vectors, as described above. However, as the virus genome of an adenovirus vector is relatively long (36 kb), there arise some problems, in actual construction of a recombinant vector, such as the complicated procedures or the low efficiency in construction processes. Examples of a method of constructing a recombinant adenovirus vector in which the E1 region has been replaced include a method of utilizing in vivo homologous recombination in a mammalian cell (the 293 cell, for example) between two plasmids (e.g., Virology 163:614-617, 1988; Nucleic Acids Res. 26:3687-3693, 1998). In such a method, the first plasmid includes the 5' end ITR (inverted terminal repeat) of the adenovirus genome, the packaging signal, the target gene and any selected portion of the virus genome. The second plasmid includes the virus genome portion which overlaps the first plasmid and the remaining portion of the virus genome which contains the 3' end ITR. However, as the possibility that the homologous recombination occurs in a mammalian cell is quite low, in the method described above, it is necessary to carry out transfection of both of the plasmids to a mammalian cell on a large scale.

30

Alternatively, as another method, the COS-TPC method has been proposed (Proc. Natl. Acad. Sci. USA 93:1320-1324, 1996). This method includes the step of transfecting a mammalian cell with a cosmid vector containing an adenovirus genome of whole length together with an expression unit of the targeted gene, and the virus DNA-TPC (terminal protein complex) which has been subjected to digestion by a restriction enzyme. In this method, by using the virus DNA-TPC, the target recombinant adenovirus vector can be efficiently retrieved. However, in the case of this method, the elimination of the parental adenovirus is insufficient, although a measure for preventing the parental adenovirus from appearing is taken by digesting the adenovirus genome by the restriction enzyme. In short, this method has a problem in terms of safety.

As a yet another method, there has been reported a method of constructing a recombinant adenovirus vector to which the Cre-loxP recombinant system is applied (J. Virol. 71:1842-1849, 1997). In this method, by the action of the Cre recombinase, a recombination between molecules (specifically, a recombination between the adenovirus as the donor and the shuttle plasmid having the expression cassette) is effected and a recombinant adenovirus vector can be constructed efficiently. However, in the case of this invention, donor virus must be prepared and there is a possibility that the donor virus remains in the final virus sample.

Further, there has been an attempt to reconstruct the whole adenovirus genome, in vitro, with using a cosmid vector. In this case, however, the complicated DNA constructing process is required prior to the transfection to a mammalian cell line, which is not practical.

Problems to be solved by the present Invention:

Prior to the aforementioned various reports and proposals regarding the method of constructing a recombinant adenovirus vector, Graham reported that, when a circular DNA constructed by inserting a small plasmid at the restriction

enzyme Xba I site, which site exists at the one location in the E1 region of the adenovirus 5 type, is transfected to a mammalian cell line (the 293 cells), the circular DNA produces the infectious virus as efficiently as the virus DNA does (EMBO J. 3:2917-2922, 1984).

5

This report suggests that a recombinant adenovirus vector can be easily constructed by replacing the E1 region or E3 region of a circular adenovirus DNA with an exogenous gene. However, when a recombinant adenovirus vector is actually constructed according to this method, there arise two problems. One is 10 the low efficiency in incorporating the expression cassette into the extremely large plasmid which contains the adenovirus genome DNA. The other problem is that the plasmid DNA portion remains in the constructed adenovirus vector.

CROSS-REFERENCE TO RELATED APPLICATION

15

Disclosure of Invention

The invention of the present application has an object to provide a novel method of easily and efficiently constructing a recombinant adenovirus vector, and genetic engineering materials for implementing the method invention.

20

The first aspect of the present invention is a method for constructing a recombinant adenovirus vector having a DNA sequence consisting of an adenovirus genome DNA and an expression cassette, which comprises:

25 constructing a recombinant cosmid/adenovirus vector by inserting and ligating a cosmid sequence having recombinase recognition sequences at both ends and the expression cassette into a site of the adenovirus genome DNA where E1 region or E1 and E3 regions are deleted;

30 cotransfected this recombinant cosmid/adenovirus vector and a recombinase-expression vector into a cell line producing adenovirus E1 protein; and

deleting the cosmid vector sequence from the recombinant cosmid/adenovirus vector in the cells.

In the method according to the first aspect of the present invention, it is preferable that the recombinase is Cre recombinase and the recognition sequences thereof are loxP sequences, or the recombinase is FLP recombinase and the recognition sequences thereof are FRT sequences. In addition, it is preferable that the cell producing adenovirus E1 protein is 293 cell derived from human fetal kidney cells.

10

The second aspect of the present invention is a method for constructing a recombinant adenovirus vector having a DNA sequence consisting of an adenovirus genome DNA and an expression cassette, which comprises:

constructing a recombinant cosmid/adenovirus vector by inserting and ligating a cosmid sequence having recombinase recognition sequences at both ends and the expression cassette into a site of the adenovirus genome DNA where E1 region or E1 and E3 regions are deleted;

transfected this recombinant cosmid/adenovirus vector into a cell line producing recombinase and adenovirus E1 protein; and

20 deleting the cosmid vector sequence from the recombinant cosmid/adenovirus vector in the cells.

In the method according to the second aspect of the present invention, it is preferable that the recombinase is Cre recombinase and the recognition sequences thereof are loxP sequences or the recombinase is FLP recombinase and the recognition sequences thereof are FRT sequences. In addition, it is preferable that the cell producing the recombinase and adenovirus E1 protein is the 293 cell derived from human fetal kidney cells which produces the recombinase.

30 The third aspect of the present invention is a cosmid/adenovirus vector,

which comprises a cosmid sequence having recombinase recognition sequences at both ends in a site of the adenovirus genome DNA where E1 region or E1 and E3 regions are deleted.

5 In the cosmid/adenovirus vector of the third aspect of the present invention, it is preferable that the recombinase is Cre recombinase and the recognition sequences thereof are loxP sequences, or the recombinase is FLP recombinase and the recognition sequences thereof are FRT sequences.

10 The fourth aspect of the present invention is a 293 cell line derived from human fetal kidney cells which produce FLP recombinase.

Specifically, in the aforementioned aspects of the present invention, "a cosmid sequence" means a linear cosmid vector sequence having recombinase 15 recognition sequences in the same direction at both ends. In addition, "a cosmid/adenovirus vector" means a circular DNA construct which comprises said cosmid sequence and the adenovirus genome DNA with the deletion of the E1 region or E1 and E3 regions. Further, "a recombinant cosmid/adenovirus vector" means a circular DNA construct produced by incorporating an expression cassette 20 into said cosmid/adenovirus vector. Yet further, "a recombinant adenovirus vector" means an adenovirus including a linear DNA sequence produced by removing the cosmid sequence from said recombinant cosmid/adenovirus vector in the infectious viral particle.

25

Brief Description of Drawings

Fig. 1 is a schematic view which shows structures of a cosmid/adenovirus vector pALC (upper) and an expression cassette (lower) constructed in example 1. 30 The adenovirus genome DNA of 34 kb is shown as a white ring and the direction of

the genome is indicated by the arrow. The cosmid vector of 7 kb is interposed by the loxP sequences shown by the black triangles, and includes therein the cos site, the kanamycin resistance gene (Km), the origin of replication (ori) that works in Escherichia coli and the ampicillin resistance gene (Ap). The expression cassette 5 consists of the CAG promoter, the mouse IL-5 cDNA, IRES, EGFP cDNA, and the poly(A) additional signal (pA). The expression cassette is inserted into the Swa I site of the pALC vector, whereby a recombinant cosmid/adenovirus vector pALC-IL-5 of example 2 is constructed.

10 Fig. 2 is a schematic view which shows the main steps of processing the recombinant adenovirus vector constructed in example 3. The pALC-IL-5 of example 2 was amplified in Escherichia coli DH10B, and the amplified pALC-IL-5 was purified. The 293 cells were transfected with the purified pALC-IL-5 and the pMC1-cre plasmid. The Cre recombinase, which expresses itself in a transient 15 manner, cuts out the cosmid sequence of 7 kb efficiently, whereby an infectious recombinant adenovirus particles containing the expression cassette of IL-5 and EGFP were eventually produced.

20 Fig. 3A is a schematic view which shows a structure of the recombinant adenovirus vector DNA constructed in example 3. One loxP (indicated by the black triangle in the drawing) of the cosmid sequence which has been removed by the Cre recombinase remains in the ligated structure of the adenovirus genome (indicated as the open bar in the drawing) and the expression cassette of IL-5 and EGFP (indicated by the black bar in the drawing). The numbers indicated on the 25 lower row of Fig. 3A represent the map unit (m.u.) of the adenovirus genome. The numbers on the upper row of Fig. 3A each represent the lengths (kb) of the fragments when the recombinant adenovirus vector DNA is digested with Xba I. Fig. 3B and Fig. 3C are photographs, each showing the pattern observed when various DNA samples were digested with Xba I and subjected to electrophoresis in 30 0.4 % (B) or 0.9 % (C) agarose gel. Specifically, lane 1 and lane 2 represent the

virus DNA produced by cotransfected the 293 cell line with pALC-IL-5 and pMC1-cre; lane 3 represents the virus DNA produced by transfecting the 293 cell line with pFG140; and lane 4 represents pALC-IL-5DNA. The DNA of the lane 1 and that of lane 2 were each prepared from the virus stocks which had been obtained
5 by different transfection processes performed independent of each other. The cosmid sequence interposed by the loxP sites is contained in the DNA fragment of 9.1 kb (lane 4, the black triangle). In the recombinant adenovirus DNA, no fragment of 9.1 kb was observed but a fragment of 2.1 kb was generated (lanes 1 and 2, the white triangle). The lane M represents the electrophoresis pattern of
10 the size marker and the size thereof is indicated on the left-side end (kb).

Figs. 4A-4D are photographs each showing the plaque formation and the expression of EGFP in the vicinity of the plaque, of the recombinant adenovirus vector constructed by example 3. In the 293 cell line which had been
15 cotransfected with pALC-IL-5 and pMC1-cre, plaques formed by the virus were observed (Figs. 4A and 4C). Similarly, in the 293 cell line which had been infected with the recombinant adenovirus vector, plaques were observed (Figs. 4B and 4D). When the fields of the photographs A and B were observed with a fluorescent microscope, fluorescent light emission of EGFP was confirmed (Figs.
20 4C and 4D).

Best Mode for Carrying Out the Invention

25 In the methods for constructing a recombinant adenovirus vector of the first and the second aspects of the present invention, the cosmid/adenovirus vector of the third aspect of the present invention is used. In the preparation of the cosmid/adenovirus vector, known clones (such as pFG140 or the like used in the Examples) may be employed as the adenovirus genome DNA (36 kb, approximately). By treating such genome DNA with an appropriate restriction
30

enzyme, nuclease or the like, DNA fragments (31-34 kb, approximately) with the deletion of the E1 region (2.0 kb, approximately) or both E1 and E3 regions (3.0 kb, approximately) can be obtained. This DNA fragment is ligated with a cosmid sequence which has been cut and linearized, whereby a circular DNA construct is 5 formed. As the resulting cosmid vector is a plasmid having the cos site of *Escherichia coli* λ phage and exogenous DNA of 30-42 kb can be inserted thereto, the cosmid vector can accommodate the aforementioned DNA fragment of approximately 34 kb. The aforementioned cosmid sequence has recombinase recognition sequences at both ends thereof. The type of the recognition 10 sequences is determined in accordance with the type of the recombinase in use. For example, the loxP sequence can be used when Cre recombinase is used, and the FRT sequence can be used when FLP recombinase is used. Specifically, the loxP sequence is a sequence of 34 bp and can be used by cutting it out from a known clone (e.g., pBS 246, which was used in the Examples, manufactured by 15 GIBCO BRL co. and other companies). Further, the FRT sequence can be used by cutting it out from the known clone pNEO β GAL (manufactured by Stratagene co. and other companies). Yet further, it is preferable that a DNA sequence having the cloning site (the restriction enzyme site) at least one site other than the adenovirus genome DNA connection site is extended at the outer side of the 20 recombinase recognition sequences of the cosmid sequence.

In the aforementioned method for constructing adenovirus vector of the present invention, a recombinant cosmid/adenovirus vector is prepared by inserting and ligating the expression cassette containing a foreign gene into the 25 circular cosmid/adenovirus vector prepared as described above. The expression cassette is a DNA fragment comprises a promoter sequence, a foreign gene (cDNA) and poly(A) signal and the like.

It should be noted that, in the methods of the first and the second aspects 30 of the present invention, a recombinant cosmid/adenovirus vector may be

produced by first connecting the cosmid vector sequence with the expression cassette and then ligating this structure with the adenovirus DNA fragment. Alternatively, a recombinant cosmid/adenovirus vector may be produced by first producing a cosmid/adenovirus vector having an expression cassette inserted thereto, the expression cassette not including any foreign gene (cDNA), and then 5 incorporating a foreign gene (cDNA) into the expression cassette.

In the method according to the first aspect of the present invention, the recombinant cosmid/adenovirus vector prepared as described above is then 10 cotransfected, together with the recombinase-expression vector, to a cell producing the adenovirus E1 protein. As the recombinase-expression vector, the Cre recombinase- or the FLP recombinase-expression vector, for example, may be used. The Cre recombinase recognizes the loxP sequence and cuts out the DNA sequence interposed by two loxP sequences (Nucleic Acids Res. 17:147-161, 1989). 15 The FLP recombinase recognizes the FRT sequence and cuts out the DNA sequence interposed by two FRT sequences (Teends Genet. 9:413-421, 1993). Accordingly, when the recombinase expression vector as described above and the aforementioned recombinant cosmid/adenovirus vector are altogether introduced 20 into a host cell, the cosmid vector sequence interposed by the loxP sequences or the FRT sequences of the circular DNA is cut out by the action of the recombinase, whereby a recombinant adenovirus vector having a linear DNA sequence comprising the adenovirus genome DNA and the expression cassette is constructed.

25 As the Cre recombinase-expression vector, any suitable known clone (such as MC1-cre plasmid employed in the Examples) may be used. As the FLP recombinase-expression vector, pOG44 (manufactured by Stratagene co.) or the like may be used.

30 As the cell producing adenovirus E1 protein, the 293 cell line derived from

human fetal kidney cells can be preferably used. However, the present invention is not limited to this example, and HeLa cells, normal cells or the like to which the E1 protein gene has been introduced in advance may be used. Further, a cell isolated from a transgenic animal to which the E1 protein gene has been 5 introduced may be used.

On the other hand, in the construction method according to the second aspect of the present invention, the recombinant cosmid/adenovirus vector constructed as described above is transfected to a cell producing recombinase and adenovirus E1 protein. Specifically, in this method, as the host cell stably produces the recombinase, transfecting the host cell only with the recombinant cosmid/adenovirus vector effects, by the action of the recombinase produced by the host cell, cutting out of the cosmid vector sequence interposed by the recombinase recognition sequences of the circular DNA, whereby a recombinant adenovirus vector having a linear DNA sequence comprising the adenovirus genome DNA and the expression cassette is constructed. As the cell producing recombinase and E1 protein, the Cre recombinase producing 293 cell line known by the references (J. Virol. 71:1842-1849, 1997; Proc. Natl. Acad. Sci. USA, 93: 13565-13570, 1996) or the Cre recombinase producing 293 cell line constructed 10 by the method in the Examples described below may be employed. In addition, the FLP recombinase producing 293 cell line which is provided, as a novel product, according to the fourth aspect of the present invention may also be employed. Further, HeLa cells or normal cells to which the E1 protein gene and the recombinase gene have been introduced in advance, or a cell isolated from a 15 transgenic animal to which the E1 protein gene and the recombinase gene have been introduced, may be used. 20

The whole length of the recombinant adenovirus vector constructed in the aforementioned manner is approximately 36 kb, which is substantially the same 25 as that of the wild type adenovirus. The recombinant adenovirus vector of the

present invention is highly infectious to cells of various animals.

The 293 cell line producing FLP recombinase of the fourth aspect of the present invention can be constructed according to any known method. For example, a 293 cell line producing FLP recombinase can be constructed by first incorporating a DNA fragment which encodes the FLP recombinase into a mammalian expression vector, and then introducing the obtained vector to the 293 cell line. The DNA fragment which encodes the FLP recombinase can be cut out, for use, from the known expression vector such as pOG44 (manufactured by Stratagene co.). As the mammalian expression vector, any suitable known vector having a promoter, a splicing region, a poly(A) additional site and the like may be used, in addition to the aforementioned vector pOG44 which can be directly used. For introducing the expression vector into the 293 cell line, any suitable known method such as the electroporation method, the calcium phosphate method, the liposome method and the DEAE dextran method can be employed. Further, a drug resistance gene (such as puromycin resistance gene) may also be incorporated into the FLP recombinase expression vector, so that such a gene functions as the selection marker of the cells to which the vector has been introduced.

20

Hereinafter, the present invention will be described in detail and more specifically by the following Examples. However, it should be noted that the present invention is not restricted to any of these Examples.

25

Example 1

Construction of a cosmid/adenovirus vector

The cosmid vector SuperCos 1 was purchased from Stratagene co. (La Jolla, CA) and the plasmid pBS246 containing the loxP sequence was purchased

from GIBCO BRL co. (Rockville, MD). The Hind III site in the region interposed by the loxP sites of pBS246 was changed to Xba I, and the BamH I site in the same region was changed to Swa I. The resulting plasmid was cut at Not I, so that a fragment of 260 bp having two loxP sites was isolated. This fragment was 5 inserted into the Not I site of the SuperCos 1 whose unique Xba I site had been disrupted in advance, whereby the aimed cosmid vector (pLC cosmid) was prepared.

10 The adenovirus genome DNA was prepared from pFG 140. The pFG 140 is a plasmid in which the whole genome of the adenovirus 5d1309 is circularized and has a plasmid vector portion of 2.2 kb at the Xba I site in the E1 region thereof. The E1 region (681-2559 bp: counted from the genome 5' end) was deleted by Bal31 nuclease, and an Xba I site was re-constructed at the site of deletion.

15 The adenovirus DNA whose E1 region had been deleted and the aforementioned pLC cosmid were cut at the Xba I site, respectively, and then ligated. The product was accommodated in the head of bacteriophage λ by the "in vitro" packaging, whereby a cosmid/adenovirus vector of 41 kb (pALC cosmid) was 20 prepared (refer to Fig. 1).

Example 2

Construction of a recombinant cosmid/adenovirus vector

25 On the downstream side of the CAG promoter (the hybrid of the immediate-early enhancer of cytomegalovirus and the chicken β actin promoter) which is known to be highly active in cells of various types, mouse interleukin 5 (mIL-5) cDNA, IRES (internal ribosome entry site) derived from EMC virus and 30 EGFP (enhanced green fluorescent protein) cDNA derived from pEGFP-N1 plasmid

were sequentially ligated. Then the Swa I site was added to both ends of the sequence, whereby a DNA fragment was prepared. This DNA fragment was incorporated into a vector derived from pHSG298 having resistance to kanamycin, and the Swa I fragment was cut out from the recombinant vector, whereby the 5 expression cassette (4.2 kb) was prepared.

The expression cassette was inserted into the Swa I site of the pALC cosmid constructed in example 1. Thereafter, the product was incorporated into the head of bacteriophage λ by the "in vitro" packaging, whereby a recombinant 10 cosmid/adenovirus vector (pALC-IL-5) was prepared. The obtained vector was amplified on a large scale in Escherichia coli DH10B, purified and then retrieved.

Example 3

15 Construction of the recombinant adenovirus vector

The recombinant cosmid/adenovirus vector (pALC-IL-5) constructed in example 2 and the Cre recombinase-expression vector (MC1-cre plasmid) were cotransfected to the 293 cell line derived from human fetal kidney cells which 20 stably produce adenovirus E1 protein. MEM (Minimum Essential Medium) containing inactivated 10 % fetal bovine serum (FBS) was used as the culture medium of the 293 cells. The cells were cultured on a petri dish or a multi-plate whose surface had been coated with gelatin.

One μ g of pALC-IL-5 and 0.1 μ g of MC1-cre plasmid were cotransfected to 25 the 293 cell line cultured in a 12-well multi-plate, using LIPOFECTAMINE (manufactured by GIBCO BRL co.) (see Fig. 2).

The cytopathic effect (CPE), which can be evaluated by the degree of 30 plaque formation, was observed within 10 days after the cotransfection. The culture fluid of the plate in which CPE was observed was centrifuged at 2,000 rpm

for 5 minutes at 4 °C, and the supernatant obtained by the centrifuge was added to the 293 cell line cultured in a flask (having the culture surface of 75 cm²) so that infection was effected. After a few days, the cells were collected from the flasks in which CPE was confirmed all over the culture surface. The collected 5 cells were subjected to the freezing-and-thawing process six times and then centrifuged at 3,500 rpm for 10 minutes at 4 °C. Thereafter, the titer of the recombinant adenovirus vector contained in the obtained supernatant was measured. The measurement was carried out by: adding a virus suspension which had been diluted in the serial manner to the 293 cell line cultured on a 10 gelatin-coated 96-well multi-plate; incubating the sample; observing presence/absence of CPE; and calculating the titer from the observed results.

In addition, as a control, only pALC-IL-5 was transfected to the 293 cell line and the plaque formation was examined.

15

The obtained results were as follows. In the case of the control in which the Cre recombinase was not present, no plaque was observed in any of the 293 cells cultured in the eight wells to which the transfection was performed separately. This result indicates that, as the length of pALC-IL-5DNA is 45 kb 20 and exceeds the length that an infectious adenovirus particle can accommodate, no virus was produced. On the contrary, in the case in which pALC-IL-5DNA was transfected together with the Cre recombinase-expression vector, CPE was observed, within eight days, in all of the 293 cells planted in the eight wells. Additional experiments were carried out repeatedly for each of the control and the 25 cotransfection cases. As a result, in all of the twenty-two wells in which the Cre recombinase co-existed with pALC-IL-5DNA, the plaque was observed.

From the aforementioned results, it is confirmed that the cosmid sequence of pALC-IL-5 was efficiently removed by the Cre recombinase which 30 temporarily expressed itself and, from the circular adenovirus vector genome of 38

kb containing the expression cassette, the infectious recombinant adenovirus vector was produced.

5

Example 4

Analysis on virus DNA

In order to confirm whether or not the cosmid sequence had been removed from the recombinant adenovirus vector constructed in example 3, the 10 structure of DNA thereof was analyzed.

The virus suspension was digested with 1 % SDS, 0.2 mg/ml proteinase K and 10 mM EDTA at 37 °C for 3 hours. The digested sample was then subjected to phenol extraction, phenol/chloroform extraction and ethanol precipitation.

15 The sample was then subjected to electrophoresis in agarose gel, and the virus DNA was extracted from the gel and purified. The virus DNA was digested at Xba I and then subjected to electrophoresis by using 0.4 % and 0.9 % agarose gel.

Fig. 3A shows the structure of the recombinant adenovirus vector genome 20 and the Xba I site therein. The virus DNA purified from the suspension of the recombinant adenovirus vector was digested at the Xba I site and then subjected to electrophoresis in 0.4 % agarose gel (Fig. 3B, lane 1 and lane 2) or in 0.9 % gel 25 (Fig. 3C, lane 1 and lane 2). The virus DNA of lane 1 and that of lane 2 were each prepared from the cell groups which had been subjected to the transfection process independently. Thereafter, the pALC-IL-5DNA was digested at the Xba I site and subjected to electrophoresis in a similar manner. The Xba I fragment containing the cosmid sequence interposed by the loxP sequences is identified as a fragment of 9.1 kb (Figs. 3B and 3C, lane 4). On the other hand, the Xba I fragment contained in the DNA of the recombinant adenovirus vector is recognized 30 as a fragment of 2.1 kb (Fig. 3C, lane 1 and lane 2). The difference between the

two fragments corresponds to the cosmid sequence interposed by the loxP in pALC (approximately 7kb). From this result, it is confirmed that the cosmid sequence in pALC-IL-5 was efficiently removed by the transient expression of the Cre recombinase, and the circular adenovirus genome of 38 kb containing the expression cassette which had been formed as a result was amplified and accommodated in virus particles, whereby the infectious recombinant adenovirus vector was produced. No DNA fragment whose size is beyond the expected range was observed. Accordingly, it is also confirmed that abnormal recombination hardly occurs in the recombinant adenovirus vector constructing process according to this method. In the case of the control in which DNA of the 293 cell line, to which the clone pFG140 including the adenovirus genome had been transfected, was digested at the Xba I site, each of the expected fragments of 34.6 kb, 2.2 kb and 1.3 kb was observed (Figs. 3B and 3C, lane 3).

15

Example 5

Expression of the gene contained in the expression cassette

In order to confirm the expression of IL-5, the culture liquid of the infected cells was retrieved and centrifuged, and the IL-5 activity in the obtained supernatant was investigated by the ELISA method. In addition, the expression of EGFP was investigated by the observation with a fluorescent microscope.

In the case in which the recombinant cosmid adenovirus vector pALC-IL-5 and pMC1-cre were cotransfected to the 293 cell line, a relatively large number of cells became EGFP positive, and as the plaque of the virus developed, a strong EGFP fluorescent light emission was observed in the vicinities of all of the plaques (Figs. 4A and 4C).

30 Next, the suspension of the recombinant adenovirus vector constructed in

example 3 was diluted, and the diluted virus vector was infected to the 293 cell line, whereby the plaque was formed. More than 30 plaques were studied, and it was confirmed that all of the plaques were surrounded by EGFP positive cells (Figs. 4B and 4D). Considering that IL-5 and EGFP are transcribed in a bicistronic manner by the CAG promoter, it is expected that the adenovirus vector which expresses EGFP will also express IL-5. Therefore, in order to confirm the expression of IL-5, the virus suspension which had been diluted by the limiting dilution method was added to the 293 cell line cultured in a 96-well multi-plate and virus clones were grown separately. In the case in which ten virus clones were studied, all of the samples were EGFP positive. The IL-5 activity in the supernatant of the culture liquid was studied by using the ELISA method. The results each showed a high value (> 10 µg/ml).

The results described above suggests that the method of the present invention enables production of recombinant adenovirus vector of extremely homogeneous quality, as well as reliable expression, by this vector, of the gene introduced into a mammalian cell.

20

Example 6

Preparation of a 293 cell line producing the Cre recombinase

The Cre recombinase gene and the IRES (internal ribosome entry site) sequence derived from the EMC virus were inserted, together with the puromycin resistance gene, into the EcoR I site of pCAGGS (Gene 108 (2): 193-199, 1991), whereby the Cre recombinase-expression plasmid pCAGGS-cre-puro was constructed. The obtained plasmid was transfected to the 293 cell line, which was cultured in a medium containing puromycin at 2 µg/ml. The Cre recombinase activity was tested by isolating the puromycin resistant colonies and 30 transfecting the 293 cell line with the reporter plasmid pCAG-CAT-Z. Specifically,

this reporter plasmid, in which chloramphenicol acetyl transferase (CAT) gene interposed by the loxP sequences is inserted between the CAG promoter and the lacZ gene, causes the expression of lacZ when the CAT gene is cut out by the action of the Cre recombinase, and thus can be used for testing the Cre recombinase production of the 293 cell line (Biochem. Biophys. Res. Commun. 17(2):393-401, 1995). By this test, a cell clone 293cre15 capable of producing the Cre recombinase was obtained.

10

Example 7**Construction of a recombinant adenovirus vector in the 293cre15**

One μ g/well of the recombinant cosmid/adenovirus vector (pALC-IL-5) constructed in example 2 was transfected to the 293cre15 prepared in example 6. 15 All of the transfected cells in the nine wells showed CPE, and strong EGFP was observed at all of the spots of CPE.

From the results described above, it is confirmed that, by using the 293 cell line producing the recombinase, the recombinant adenovirus vector can be 20 efficiently constructed from the recombinant cosmid/adenovirus vector, without employing the recombinase expression vector.

Example 8**Preparation of 293 cell line producing the FLP recombinase**

The FLP recombinase gene and the IRES (internal ribosome entry site) sequence derived from the EMC virus were inserted, together with the puromycin resistance gene, into the downstream of the pgk (phosphoglycerate kinase) promoter, whereby the FLP recombinase-expression plasmid pgk-FLP-puro was 30

constructed. The obtained plasmid was transfected to the 293 cell line, which was cultured in a medium containing puromycin at 2 µg/ml. The FLP recombinase activity was tested by isolating the puromycin resistant colonies and transfecting the 293 cell line with the reporter plasmid pNEO β GAL. Specifically,

5 this reporter plasmid, in which the neomycin resistance gene interposed by the FRT sequences is inserted midway of the lacZ gene located on the downstream side of the SV40 promoter, causes the expression of lacZ when the neomycin resistance gene is cut out by the action of the FLP recombinase, and thus can be used for testing the FLP recombinase production of the 293 cell line. By this test,

10 a cell clone 293FLP capable of producing the FLP recombinase was obtained.

Industrial applicability

As described above in detail, the present invention allows easily and efficiently producing a recombinant adenovirus vector which is infectious to a mammalian cell. In the conventional method of constructing a recombinant adenovirus vector by using homologous recombination, there is a risk that a recombinant vector of unexpected type is produced and the production process thereof is complicated and time-consuming. On the contrary, the method of the present invention does not necessitate such complicated processes and allows reliable production of a recombinant vector having desired structure and function. Further, the method of the present invention allows production of a recombinant adenovirus vector by using a 293 cell line which has been used over no less than seventy passages, while the conventional method employing homologous recombination does not allow employing a 293 cell line which has been used more than 50 passages.

Accordingly, by the method and material provided by the present invention, the analysis of gene function by using a mammalian cell can be facilitated. In addition, the development of a vector used for gene therapy can

also be facilitated.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

CLAIMS

1. A method for constructing a recombinant adenovirus vector having a DNA sequence consisting of an adenovirus genome DNA and an expression cassette, 5 which comprises:

constructing a recombinant cosmid/adenovirus vector by inserting and ligating a cosmid sequence having recombinase recognition sequences at both ends and the expression cassette into a site of the adenovirus genome DNA where E1 region or E1 and E3 regions are deleted;

10 cotransfected this recombinant cosmid/adenovirus vector and a recombinase-expression vector into a cell line producing adenovirus E1 protein; and

deleting the cosmid vector sequence from the recombinant cosmid/adenovirus vector in the cells.

15 2. The method according to claim 1, wherein the recombinase is Cre recombinase and the recognition sequences thereof are loxP sequences.

20 3. The method according to claim 1, wherein the recombinase is FLP recombinase and the recognition sequences thereof are FRT sequences.

4. The method according to any of claims 1 to 3, wherein the cell line producing adenovirus E1 protein is 293 cell derived from human fetal kidney cells.

25 5. A method for constructing a recombinant adenovirus vector having a DNA sequence consisting of an adenovirus genome DNA and an expression cassette, which comprises:

constructing a recombinant cosmid/adenovirus vector by inserting and ligating a cosmid sequence having recombinase recognition sequences at both 30 ends and the expression cassette into a site of the adenovirus genome DNA where

E1 region or E1 and E3 regions are deleted;

transfected this recombinant cosmid/adenovirus vector into a cell line producing recombinase and adenovirus E1 protein; and

5 deleting the cosmid vector sequence from the recombinant cosmid/adenovirus vector in the cells.

6. The method according to claim 5, wherein the recombinase is Cre recombinase and the recognition sequences thereof are loxP sequences.

10 7. The method according to claim 5, wherein the recombinase is FLP recombinase and the recognition sequences thereof are FRT sequences.

15 8. The method according to any of claims 5 to 7, wherein the cell line producing recombinase and adenovirus E1 protein is 293 cell derived from human fetal kidney cells which produces the recombinase.

9. A cosmid/adenovirus vector, which comprises a cosmid sequence having recombinase recognition sequences at both ends in a site of the adenovirus genome DNA where E1 region or E1 and E3 regions are deleted.

20 10. The cosmid/adenovirus vector of claim 9, wherein the recombinase is Cre recombinase and the recognition sequences thereof are loxP sequences.

25 11. The cosmid/adenovirus vector of claim 9, wherein the recombinase is FLP recombinase and the recognition sequences thereof are FRT sequences.

12. A 293 cell line derived from human fetal kidney cells, which produces FLP recombinase.


ABSTRACT

A recombinant adenovirus vector comprising an adenovirus genome DNA and an expression cassette is produced by inserting and ligating a cosmid sequence having recombinase recognition sequences at both ends and the expression cassette into either deletion sites of the adenovirus genome DNA with the deletion of the E1 region or E1 and E3 regions to thereby construct a recombinant cosmid/adenovirus vector; cotransfected this recombinant cosmid/adenovirus vector and a recombinase-expression vector into a cell line producing adenovirus E1 protein; and deleting the cosmid vector sequence from the recombinant cosmid/adenovirus vector in the cells. This method makes it possible to conveniently and efficiently construct a recombinant adenovirus vector.

JAPANESE ORIGINAL


1/4

Fig. 1



2/4




Fig. 2



10/031396

3/4


Fig. 3

A**B****C**

10/031396

4/4

Fig. 4



C

D



DECLARATION AND POWER OF ATTORNEY FOR U.S. PATENT APPLICATION

(X) Original () Supplemental () Substitute (X) PCT () DESIGN

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Title: A METHOD FOR CONSTRUCTING RECOMBINANT ADENOVIRUS VECTOR

of which is described and claimed in:

(the attached specification, or
 the specification in application Serial No. , filed January 18, 2002, and with amendments through
 , or
 the specification in International Application No. PCT/JP00/04815, filed July 18, 2000, and as amended on
(if applicable).

I hereby state that I have reviewed and understand the content of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge my duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim priority benefits under Title 35, United States Code, §119 (and §172 if this application is for a Design) of any application(s) for patent or inventor's certificate listed below and have also identified below any application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

COUNTRY	APPLICATION NO.	DATE OF FILING	PRIORITY CLAIMED
Japan	1999-205355	July 19, 1999	Yes

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	U.S. FILING DATE	STATUS: PATENTED, PENDING, ABANDONED

And I hereby appoint Michael R. Davis, Reg. No. 25,134; Matthew M. Jacob, Reg. No. 25,154; Warren M. Cheek, Jr., Reg. No. 33,367; Nils Pedersen, Reg. No. 33,145; Charles R. Watts, Reg. No. 33,142; and Michael S. Huppert, Reg. No. 40,268, who together constitute the firm of WENDEROTH, LIND & PONACK, L.L.P., as well as any other attorneys and agents associated with Customer No. 000513, to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected therewith.

I hereby authorize the U.S. attorneys and agents named herein to accept and follow instructions from NISHIZAWA & ASSOCIATES as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and myself. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by me.

Direct Correspondence to Customer No:



000513

PATENT TRADEMARK OFFICE

Direct Telephone Calls to:

WENDEROTH, LIND & PONACK, L.L.P.
2033 "K" Street, N.W., Suite 800
Washington, D.C. 20006-1021

Phone: (202) 721-8200
Fax: (202) 721-8250

Full Name of First Inventor	FAMILY NAME <u>MIYAZAKI</u>	FIRST GIVEN NAME <u>Junichi</u>	SECOND GIVEN NAME	
Residence & Citizenship	CITY <u>Osaka</u>	STATE OR COUNTRY <u>Japan</u>	COUNTRY OF CITIZENSHIP <u>JPX</u>	
Post Office Address	ADDRESS <u>6-8-810, Kamiyamada, Saita-shi, Osaka, Japan</u>	CITY	STATE OR COUNTRY	ZIP CODE
Full Name of Second Inventor	FAMILY NAME <u>TASHIRO</u>	FIRST GIVEN NAME <u>Fumi</u>	SECOND GIVEN NAME	
Residence & Citizenship	CITY <u>Osaka</u>	STATE OR COUNTRY <u>Japan</u>	COUNTRY OF CITIZENSHIP <u>JPX</u>	
Post Office Address	ADDRESS <u>306, Muris-Senrikita, 26-12, Toyokawa 4-chome, Ibaraki-shi, Osaka, Japan</u>	CITY	STATE OR COUNTRY	ZIP CODE
Full Name of Third Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME	
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP	
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
Full Name of Fourth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME	
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP	
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
Full Name of Fifth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME	
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP	
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE
Full Name of Sixth Inventor	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME	
Residence & Citizenship	CITY	STATE OR COUNTRY	COUNTRY OF CITIZENSHIP	
Post Office Address	ADDRESS	CITY	STATE OR COUNTRY	ZIP CODE

I further declare that all statements made herein of my own knowledge are true, and that all statements on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

1st Inventor Junichi Miyazaki Date February 6, 2002
Junichi MIYAZAKI

2nd Inventor Fumi Tashiro Date February 6, 2002
Fumi TASHIRO

3rd Inventor _____ Date _____

4th Inventor _____ Date _____

5th Inventor _____ Date _____

6th Inventor _____ Date _____


The above application may be more particularly identified as follows:

U.S. Application Serial No. _____ Filing Date January 18, 2002

Applicant Reference Number 00-F-025US/YS Atty Docket No. 2002 0053A

Title of Invention A METHOD FOR CONSTRUCTING RECOMBINANT ADENOVIRUS VECTOR

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

Page(s) _____ of _____ were not present
for scanning. (Document title)

Page(s) _____ of _____ were not present
for scanning. (Document title)

Scanned copy is best available.

Drawing figures 3-4 are too dark.